Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a leading cause of cancer death, and medical treatment options are limited. The multikinase inhibitor sorafenib was the first approved drug widely used for systemic therapy in advanced HCC. Sorafenib might affect polyunsaturated fatty acids (PUFA)-derived epoxygenat...

Descripción completa

Detalles Bibliográficos
Autores principales: Leineweber, Can G., Rabehl, Miriam, Pietzner, Anne, Rohwer, Nadine, Rothe, Michael, Pech, Maciej, Sangro, Bruno, Sharma, Rohini, Verslype, Chris, Basu, Bristi, Sengel, Christian, Ricke, Jens, Schebb, Nils Helge, Weylandt, Karsten-H., Benckert, Julia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020374/
https://www.ncbi.nlm.nih.gov/pubmed/36937889
http://dx.doi.org/10.3389/fphar.2023.1124214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020374/
https://www.ncbi.nlm.nih.gov/pubmed/36937889
http://dx.doi.org/10.3389/fphar.2023.1124214

Ejemplares similares